Immune Protocols, Cancer
In this video, Darryl See spends about 27 minutes speaking on "Immune Protocols, Cancer" at the 29th Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About Darryl See
DARRYL SEE, M.D. is adjunct Professor of Research at the Institute of Molecular Medicine. He graduated Cum Laude as an undergraduate from the University of California, San Diego and from the Medical School at University of California Irvine as a recipient of the top medical honor, membership in Alpha Omega Alpha. As a Fellow in Infectious Diseases, Dr. See won the University Excellence in Research Award during both years and most recently won the 1998 Fisher Institute’s Edward’s Award for excellence in basic research.
Board certified in both Internal Medicine and Infectious Diseases, Dr. See has published several textbook chapters and over 30 peer-reviewed journal articles on chronic viral illnesses and immunologic disorders. He has presented multiple research projects at conferences around the world and has been a featured speaker at many. Dr. See pioneered the use of Artificial Intelligence and Expert Computer Programs in the management of AIDS. He was a Co-Investigator on 2 National Institutes of Health (NIH) research grants, trained at the NIH in Molecular Biology and has been the principal investigator in dozens of clinical trials.
Transcription
Thank you, everyone. You only took a couple minutes of my time, I really appreciate that. Well, let's roll with some really refreshing to see so many of you out here on a Monday afternoon.
It must be a good speaker coming up a little bit later or something. Anyway, it's great to see all of you up here. For those of you that don't know me, which is probably most of you. My name is Darryl Darryl C. I was a former associate clinical professor of medicine infectious diseases, oddly enough, at the University of California, Berkeley, and very, very interested in immunology of cancer and have been consulting in clinical trial wells and with oncologists for about 12 years now continue to do so. And right now, I'm taking some time off to catch up on publications. I have about eight of them that I'm writing up right now. Unsay now for peer review, et cetera. It's one of those publications that I'm going to present to you this afternoon. And a perfect follow-up actually to the excellent lecture by John by John Boyd, because it's my philosophy as well that a combination therapy, mostly with natural products, is absolutely what is needed for all stages of cancer, essentially.
So we'll be showing you a study that is quite a pilot study, but quite a complex study with a large number of nutraceuticals that we believe works synergistically. I'll show you a little bit about the pathogenesis, about the pathogenesis there. But again, our philosophies are completely, completely conjoin in each other. And that in that combination, therapies are probably going to be the only viable way of treating this terrible disease down the line.
It's the name of our study them and present today is nutraceutical advanced protocols used for immune enhancement. And we used some laboratory markers to determine if we were improving the immune system.
Some of you may know The Lancet to The Lancet article.
And just here in 2001, about four months ago, was actually the first article ever to show proofs and prove scientifically that the immune system was a primary defense against developing cancer. And also implying that is a very important tool in dealing with cancer. Once a person has it really a landmark paper done in Japan over 11 years and we looked at two of the most important, but we believe or two of the most important markers in fighting cancer, which would be tumor necrosis factor at the level of the cancer cell, not serum TANF.
I'll explain the difference in a minute. And natural killer cell function. We'd like to extend great thanks to IMU Plus